Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Adel Mandl
Characterization of structural, biochemical, pharmacokinetic, and pharmacodynamic properties of the LSD1 inhibitor bomedemstat in preclinical models
Lysine-specific demethylase 1 (LSD1) is emerging as a critical mediator of tumor progression in metastatic castration-resistant prostate cancer (mCRPC). Neuroendocrine prostate cancer (NEPC) is increasingly recognized as an adaptive mechanism of resistance in mCRPC patients failing androgen receptor axis-targeted therapies. Safe and effective LSD1 inhibitors are necessary to determine antitumor response in prostate cancer models.
LSD1 inhibition suppresses ASCL1 and de-represses YAP1 to drive potent activity against neuroendocrine prostate cancer
Abstract Lysine-specific demethylase 1 (LSD1 or KDM1A) has emerged as a critical mediator of tumor progression in metastatic castration-resistant prostate cancer (mCRPC). Among mCRPC subtypes, neuroendocrine prostate cancer (NEPC) is an exceptionally aggressive variant driven by lineage plasticity, an adaptive resistance mechanism to androgen receptor axis-targeted therapies. Our study shows that LSD1 expression is elevated in NEPC and associated with unfavorable clinical outcomes.
c-MET inhibition: novel treatment for sporadic and MEN1-associated GEP NETs
Introduction Gastroenteropancreatic neuroendocrine tumors (GEP NETs) represent a heterogeneous group of tumors with an unpredictable clinical course and varying degrees of malignancy. These neoplasms arise from neuroendocrine cells and are characterized by their ability to produce and secrete peptide hormones that can result in syndromes of hormonal excess. While they are rare, the incidence of NETs in the United States has increased 6.4-fold over the past 40 years (Dasari et al. 2017).
c-MET Inhibition: Novel Treatment for Sporadic and MEN1-associated GEP NET
Gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) comprise a heterogenous and diverse group of neoplasms arising from a common neuroendocrine cell origin. The majority of these tumors occur sporadically while ~20% manifest within the context of hereditary syndromes.
Colonic pseudo-obstruction in a patient with Sheehan’s syndrome
Colonic pseudo-obstruction in a patient with Sheehan’s syndrome Navneet Kaur1, Ulrich Schubart2,3 and Adel Mandl1 1 Jacobi Medical Center, Internal Medicine, Bronx, New York, USA 2 Endocrinology, Jacobi Medical Center, Bronx, New York, USA 3 Albert Einstein College of Medicine, Yeshiva University, Bronx, New York, USA Correspondence to Dr Navneet Kaur, navneetdr85{at}gmail.com Abstract A 56-year-old woman with a history of hypothyroidism and chronic constipation presented with an acute...
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Adel
Contact Adel, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack